Characteristics of patients on standard or prolonged treatment with bedaquiline
| Standard treatment with bedaquiline | Prolonged treatment with bedaquiline | Overall | p-value# | |
| Patients n | 83 | 30 | 113 | – |
| Patient characteristics | ||||
| Median (IQR) age | 37 (29–47) | 38 (31–51) | 38 (30–47) | 0.74 |
| Male | 60 (72.3) | 21 (70) | 81 (71.7) | 0.99 |
| HIV infection | 4 (4.8) | 0 (0) | 4 (3.5) | 0.52 |
| Thyroid disease | 3 (3.6) | 0 (0) | 3 (2.7) | 0.69 |
| Alcohol abuse disorder | 11 (13.3) | 6 (20) | 17 (15) | 0.56 |
| Diabetes | 6 (7.2) | 1 (3.3) | 7 (6.2) | 0.75 |
| Median (IQR) baseline QTcF interval¶ | 388 (360–407) | 386 (362–416) | 387 (360–410) | 0.63 |
| Microbiological/radiological findings | ||||
| AFB smear-positive at baseline+ | 21 (25.3) | 23 (76.7) | 44 (38.9) | <0.01 |
| Cavitation on chest radiograph | 50 (60.2) | 22 (73.3) | 72 (63.7) | 0.29 |
| Previous treatment | ||||
| Never previously treated for TB | 9 (10.8) | 1 (3.3) | 10 (8.8) | 0.39 |
| Previously treated with first-line drugs | 12 (14.5) | 1 (3.3) | 13 (11.5) | 0.19 |
| Previously treated with second-line drugs | 62 (74.7) | 28 (93.3) | 90 (79.6) | 0.06 |
| DST | ||||
| DST performed for fluoroquinolones | 78 (94) | 30 (100) | 108 (95.6) | 0.39 |
| If DST performed, fluoroquinolone resistant | 67 (85.9) | 27 (90) | 94 (87) | 0.80 |
| DST performed for second-line injectables | 79 (95.2) | 30 (100) | 109 (96.5) | 0.52 |
| If DST performed, second-line injectable resistant | 60 (75.9) | 22 (73.3) | 82 (75.2) | 0.97 |
Data reported as n (%) unless otherwise specified. HIV: human immunodeficiency virus; AFB: acid-fast bacilli; TB: tuberculosis; DST: drug susceptibility test. #: the following tests were used to calculate p-value: for medians Kruskal–Wallis Test; for proportions Chi square test; for rates Exact Fisher two-sided test. ¶: missing for five patients (two in the bedaquiline 6 months group and three in the bedaquiline >6 months group). +: missing for one patient (one in the bedaquiline 6 months group).